文献速递乳腺癌

早期乳腺癌保乳术后单纯组织间多导管近距离放疗加速部分乳腺照射与全乳照射加瘤床补量的比较:GEC-ESTRO 随机 3 期非劣效试验 10 年结果

Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial.
PubMed 文献 · Lancet Oncol · 2023-02-01

这项在 7 国 16 家医院开展的随机 3 期非劣效试验,比较早期乳腺癌保乳术后多导管近距离放疗加速部分乳腺照射(APBI)与全乳照射的 10 年疗效。中位随访 10.36 年时,两组 10 年局部复发率差异为 1.93%(95%CI -0.018 至 3.87;p=0.074),APBI 组治疗相关 3 级晚期副作用显著更少。作者认为 APBI 在疗效上是全乳照射的有价值替代方案,且晚期副作用更少。

要点

  • 中位随访 10.36 年,全乳照射组 10 年局部复发率 1.58%,APBI 组 3.51%,差异 1.93%(95%CI -0.018 至 3.87;p=0.074)。
  • APBI 组治疗相关 3 级晚期副作用发生率显著低于全乳照射组(1% vs 4%;p=0.021)。
  • 两组均未观察到 4 级不良事件或治疗相关死亡,最常见 3 级不良事件为纤维化。

核心结论

  • 保乳术后使用多导管近距离放疗的 APBI 在疗效上是全乳照射的有价值替代方案,且与更少的晚期副作用相关。

研究设计与样本

  • 随机、3 期、非劣效试验,在奥地利、捷克共和国、德国、匈牙利、波兰、西班牙和瑞士的 16 家医院和医疗中心开展。
  • 纳入 40 岁及以上、接受保乳手术的早期浸润性乳腺癌或导管原位癌患者,中央随机(1:1)分配至全乳照射组或 APBI 组。
  • 全乳照射为 5 周内 25 次每日 50 Gy,瘤床追加 10 Gy;APBI 为 5 天内 30.1 Gy(7 次)或 32.0 Gy(8 次)高剂量率近距离放疗,或 5 个治疗日内 50 Gy 脉冲剂量率近距离放疗。
  • 主要终点为同侧局部复发,在意向治疗人群(as-treated)中分析;非劣效界值为复发率差异 3 个百分点(针对 5 年结果定义)。
  • 2004 年 4 月 20 日至 2009 年 7 月 30 日共随机 1328 例女性患者(全乳照射组 n=673,APBI 组 n=655),其中全乳照射组 551 例、APBI 组 633 例符合分析条件。

主要发现

  • 中位随访 10.36 年(IQR 9.12-11.28),全乳照射组 10 年局部复发率为 1.58%(95%CI 0.37 至 2.8),APBI 组为 3.51%(95%CI 1.99 至 5.03)。
  • 两组 10 年局部复发率差异为 1.93%(95%CI -0.018 至 3.87;p=0.074)。
  • 在 7.5 年或 10 年随访或两者时,不良事件多为 1 级和 2 级,全乳照射组 393 例中 234 例(60%),APBI 组 470 例中 314 例(67%)。
  • APBI 组治疗相关 3 级晚期副作用发生率显著低于全乳照射组(全乳照射组 393 例中 17 例[4%] vs APBI 组 470 例中 7 例[1%];p=0.021;在 7.5 年或 10 年随访或两者时)。
  • 10 年时两组最常见的 3 级不良事件均为纤维化(全乳照射组 313 例中 6 例[2%] vs APBI 组 375 例中 3 例[1%],p=0.56);未观察到 4 级不良事件或治疗相关死亡。

关键数值与推荐

  • 非劣效界值为局部复发率差异 3 个百分点(针对 5 年结果定义)。
  • 全乳照射方案:5 周内 25 次每日 50 Gy,瘤床追加 10 Gy。
  • APBI 方案:5 天内 30.1 Gy(7 次)或 32.0 Gy(8 次)高剂量率近距离放疗,或 5 个治疗日内 50 Gy 脉冲剂量率近距离放疗。

临床怎么用

  • 作者认为,早期乳腺癌保乳术后使用多导管近距离放疗的 APBI 在疗效上是全乳照射的有价值替代方案,且与更少的晚期副作用相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Several randomised, phase 3 trials have investigated the value of different techniques of accelerated partial breast irradiation (APBI) for patients with early breast cancer after breast-conserving surgery compared with whole-breast irradiation. In a phase 3 randomised trial, we evaluated whether APBI using multicatheter brachytherapy is non-inferior compared with whole-breast irradiation. Here, we present the 10-year follow-up results. METHODS: We did a randomised, phase 3, non-inferiority trial at 16 hospitals and medical centres in Austria, Czech Republic, Germany, Hungary, Poland, Spain, and Switzerland. Patients aged 40 years or older with early invasive breast cancer or ductal carcinoma in situ treated with breast-conserving surgery were centrally randomly assigned (1:1) to receive either whole-breast irradiation or APBI using multicatheter brachytherapy. Whole-breast irradiation was delivered in 25 daily fractions of 50 Gy over 5 weeks, with a supplemental boost of 10 Gy to the tumour bed, and APBI was delivered as 30·1 Gy (seven fractions) and 32·0 Gy (eight fractions) of high-dose-rate brachytherapy in 5 days or as 50 Gy of pulsed-dose-rate brachytherapy over 5 treatment days. Neither patients nor investigators were masked to treatment allocation. The primary endpoint was ipsilateral local recurrence, analysed in the as-treated population; the non-inferiority margin for the recurrence rate difference (defined for 5-year results) was 3 percentage points. The trial is registered with ClinicalTrials.gov, NCT00402519; the trial is complete. FINDINGS: Between April 20, 2004, and July 30, 2009, 1328 female patients were randomly assigned to whole breast irradiation (n=673) or APBI (n=655), of whom 551 in the whole-breast irradiation group and 633 in the APBI group were eligible for analysis. At a median follow-up of 10·36 years (IQR 9·12-11·28), the 10-year local recurrence rates were 1·58% (95% CI 0·37 to 2·8) in the whole-breast irradiation group and 3·51% (1·99 to 5·03) in the APBI group. The difference in 10-year rates between the groups was 1·93% (95% CI -0·018 to 3·87; p=0·074). Adverse events were mostly grade 1 and 2, in 234 (60%) of 393 participants in the whole-breast irradiation group and 314 (67%) of 470 participants in the APBI group, at 7·5-year or 10-year follow-up, or both. Patients in the APBI group had a significantly lower incidence of treatment-related grade 3 late side-effects than those in the whole-breast irradiation group (17 [4%] of 393 for whole-breast irradiation vs seven [1%] of 470 for APBI; p=0·021; at 7·5-year or 10-year follow-up, or both). At 10 years, the most common type of grade 3 adverse event in both treatment groups was fibrosis (six [2%] of 313 patients for whole-breast irradiation and three [1%] of 375 patients for APBI, p=0·56). No grade 4 adverse events or treatment-related deaths have been observed. INTERPRETATION: Postoperative APBI using multicatheter brachytherapy after breast-conserving surgery in patients with early breast cancer is a valuable alternative to whole-breast irradiation in terms of treatment efficacy and is associated with fewer late side-effects. FUNDING: German Cancer Aid, Germany.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Strnad V, Polgár C, Ott OJ, et al. Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol. 2023. PMID: 36738756. doi:10.1016/S1470-2045(23)00018-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。